Clinical Trial Update: Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the additional efficacy and safety of the fixed-dose combination olmesartan medoxomil 20 mg / hydrochlorothiazide 12.5 mg in Chinese pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Olmesartan medoxomil-hydrochlorothiazide (olmesartan medoxomil-hydrochlorothiazide)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED